

prevented about one case of malaria per child over the same period.

According to the WHO's 2014 world malaria report (http://www.who.int/malaria/publications/world_malaria_report_2014/en/), there were 198 million cases of malaria worldwide in 2013 and the disease killed an estimated 584,000 people. Of those deaths, 90% occurred in sub-Saharan Africa, where 83% were children under the age of 5. Extrapolating the vaccine's success to the entire region, even at the one-case-per-child rate, "that's 30 million cases of malaria prevented" every year for three or four years, Slaoui says. Given the significant burden of treating those children, the vaccine could be "an enormous benefit to public health."

As for why the vaccine works some of the time but far from all of the time, Slaoui notes the tenacity and ubiquity of the parasite. "On average, a child [in sub-Saharan Africa] gets a malaria-infected mosquito bite about once a week," he says. "You can protect against 51 of those bites over a year and fail to protect for one and the child might get malaria. It's an incredibly high hurdle."

The European regulator reviewed the vaccine under Article 58, which allows the agency to recommend a vaccine or medicine for use outside the European Union. With this endorsement in place, the WHO can now formulate a policy

recommendation, and individual nations can determine how to use the vaccine—and how to fund its use—alongside existing malaria efforts. The WHO's Strategic Advisory Group of Experts on Immunization and its Malaria Policy Advisory Committee are scheduled to meet in November 2015.

A future malaria vaccine arsenal might include a so-called heterologous prime-boost approach, whereby two different vaccines containing the same antigen are given sequentially to drive a greater immune response to the parasite. Several prime-boost trials are ongoing, though a combination of RTS,S and an adenoviral vector expressing CSP from Johnson & Johnson's Crucell vaccine division in Leiden, The Netherlands, was no more effective than Mosquirix alone, according to recently published results of a phase 2 trial (*PLoS One* 10, e0131571, 2015). A prime-boost strategy from a group led by Adrian Hill, director of the Jenner Institute in Oxford, UK, has shown promise in early trials using a different sporozoite antigen, ME-TRAP (multiple epitope-thrombospondin-related adhesion protein) (*J. Infect. Dis.* 211, 1076–1086, 2015.).

WHO spokesperson Gregory Härtl calls the vaccine a "big step forward," noting that its success will be held up as a yardstick for subsequent attempts at preventing the disease. But there's

room for a single malaria vaccine with greater efficacy. "We have to find the right targets, the right antigens for T cells to recognize and use as a homing beacon for clearing the pathogen," says Chip Clark, CEO of Cambridge, MA-based Genocea Biosciences. Genocea's discovery efforts in malaria are supported by the Bill and Melinda Gates Foundation. The company's platform allows it to profile individuals' T-cell responses to the parasite and identify differences. With this strategy, the company hopes to find key T-cell antigens that could be added to an existing vaccine like Mosquirix or form the basis of something new. Among other approaches in early testing highlighted by PATH's Kaslow are a live, attenuated vaccine developed by Rockville, Maryland-based Sanaria that may generate a strong response to the parasite in the liver. Another strategy is a vaccine to block transmission of the parasite within the mosquito midgut.

GSK is developing a second-generation version of Mosquirix, which so far in early-stage trials in healthy volunteers is demonstrating "much higher" efficacy than what the company observed with Mosquirix at the same stage of development, says GSK's Slaoui. "It's a tweak," he says. "A highly scientific tweak with a strong rationale behind it. It's remarkable."

Chris Morrison Yardley, Pennsylvania

© 2015 Nature America, Inc. All rights reserved.



Around the world in a month

CANADA
 Johnson & Johnson Innovation will open its first J Labs biotech incubator in Toronto in Spring 2016, with plans to house up to 50 startups in over 40,000 square feet of laboratory and office space. J&J's partners include the University of Toronto, the Ontario government and MaRS Discovery District.

UNITED KINGDOM
 Stevenage Borough Council awards planning permission for the construction of a cell therapy manufacturing plant. The 7,200-square meter, \$87-million facility is part of the Cell Therapy Catapult, and it aims to provide late-phase and commercial cell therapy manufacturing capabilities for UK biotech companies. The plant is slated for completion in 2017 and will provide up to 150 new jobs.

MALAYSIA
 Malaysia's Inno Bio Ventures enters an agreement with Iran's Aryogen Biopharma, to market and distribute locally manufactured biosimilar products to Vietnam, Laos, Cambodia, Myanmar and the Philippines. The biosimilar drugs, which include rituximab (Rituxan), trastuzumab (Herceptin), etanercept (Enbrel) and Factor VII (eptacog alpha), will be priced 30–40% lower than their branded counterparts.

AUSTRALIA
 The state of Western Australia moves to repeal laws that stop farmers growing commonwealth-approved biotech crops. The GM Crops Free Areas Act is likely to be passed as legislation in November. GM technology supporters, including farming groups, lobbied the government to make repealing the law a priority despite opposition from organic farmers and green groups. The WA state has been growing GM canola since 2010.

JAPAN
 The National Cancer Center of Japan launches a research project called Scrum-Japan to gather genomic information from thousands of cancer patients to develop individualized treatments. The project, in conjunction with 13 pharma firms including Takeda, Astellas and Pfizer, will focus on ~150 genes linked to cancers.

Map: © iStockphoto; Flags: Jelena Zanic/ Hemera/Thinkstock